Hwang Sean T, Ballout Ahmad A, Sonti Anup N, Kapyur Amitha, Kirsch Claudia, Singh Neeraj, Markowitz Noah, Leung Tung Ming, Chong Derek J, Temes Richard, Pacia Steven V, Kuzniecky Ruben I, Najjar Souhel
Department of Neurology (STH, AAB, NS, DJC, SVP, RIK, SN), Zucker School of Medicine; Zucker School of Medicine (ANS, AK); Department of Neuroradiology (CK), Zucker School of Medicine, Hempstead; Feinstein Institutes for Medical Research (NM, TML), Manhasset; and Department of Neurosurgery (RT), Zucker School of Medicine, Hempstead, NY.
Neurol Clin Pract. 2022 Feb;12(1):52-59. doi: 10.1212/CPJ.0000000000001136.
To identify the prevalence of EEG abnormalities in patients with coronavirus disease 2019 (COVID-19) with neurologic changes, their associated neuroimaging abnormalities, and rates of mortality.
A retrospective case series of 192 adult COVID-19-positive inpatients with EEG performed between March and June 2020 at 4 hospitals: 161 undergoing continuous, 24 routine, and 7 reduced montage EEG. Study indication, epilepsy history, intubation status, administration of sedatives or antiseizure medications (ASMs), metabolic abnormalities, neuroimaging pathology associated with epileptiform abnormalities, and in-hospital mortality were analyzed.
EEG indications included encephalopathy (54.7%), seizure (18.2%), coma (17.2%), focal deficit (5.2%), and abnormal movements (4.6%). Epileptiform abnormalities occurred in 39.6% of patients: focal intermittent epileptiform discharges in 25.0%, lateralized periodic discharges in 6.3%, and generalized periodic discharges in 19.3%. Seizures were recorded in 8 patients, 3 with status epilepticus. ASM administration, epilepsy history, and older age were associated with epileptiform abnormalities. Only 26.3% of patients presented with any epileptiform abnormality, 37.5% with electrographic seizures, and 25.7% patients with clinical seizures had known epilepsy. Background findings included generalized slowing (88.5%), focal slowing (15.6%), burst suppression (3.6%), attenuation (3.1%), and normal EEG (3.1%). Neuroimaging pathology was identified in 67.1% of patients with epileptiform abnormalities, over two-thirds acute. In-hospital mortality was 39.5% for patients with epileptiform abnormalities and 36.2% for those without. Risk factors for mortality were coma and ventilator support at time of EEG.
This article highlights the range of EEG abnormalities frequently associated with acute neuroimaging abnormalities in COVID-19. Mortality rates were high, particularly for patients in coma requiring mechanical ventilation. These findings may guide the prognosis and management of patients with COVID-19 and neurologic changes.
确定2019冠状病毒病(COVID-19)伴有神经功能改变的患者中脑电图异常的患病率、相关神经影像学异常及死亡率。
对2020年3月至6月期间在4家医院进行脑电图检查的192例成年COVID-19阳性住院患者进行回顾性病例系列研究:161例进行持续脑电图检查,24例进行常规脑电图检查,7例进行简化导联脑电图检查。分析研究指征、癫痫病史、插管状态、镇静剂或抗癫痫药物(ASM)的使用、代谢异常、与癫痫样异常相关的神经影像学病理以及住院死亡率。
脑电图检查指征包括脑病(54.7%)、癫痫发作(18.2%)、昏迷(17.2%)、局灶性缺损(5.2%)和异常运动(4.6%)。39.6%的患者出现癫痫样异常:局灶性间歇性癫痫样放电占25.0%,侧化周期性放电占6.3%,全身性周期性放电占19.3%。8例患者记录到癫痫发作,3例为癫痫持续状态。ASM的使用、癫痫病史和年龄较大与癫痫样异常有关。仅26.3%的患者出现任何癫痫样异常,37.5%的患者出现脑电图癫痫发作,25.7%有临床癫痫发作的患者有已知癫痫病史。背景检查结果包括广泛性慢波(88.5%)、局灶性慢波(15.6%)、爆发抑制(3.6%)、波幅衰减(3.1%)和脑电图正常(3.1%)。67.1%有癫痫样异常的患者发现神经影像学病理改变,其中超过三分之二为急性病变。有癫痫样异常的患者住院死亡率为39.5%,无癫痫样异常的患者为36.2%。死亡率的危险因素是脑电图检查时的昏迷和呼吸机支持。
本文强调了COVID-19中经常与急性神经影像学异常相关的脑电图异常范围。死亡率很高,尤其是对于需要机械通气的昏迷患者。这些发现可能指导COVID-19伴有神经功能改变患者的预后评估和管理。